Margetuximab, an Fc-optimized mAb that targets HER2 with the same binding epitope as trastuzumab, affects the cell’s ability to kill tumor cells by increasing the affinity for activated Fc receptor (CD16A) and by decreasing the affinity for inhibitory Fc receptor (CD32B) and ADCC effects [54]. The gene discussed is ERBB2; the disease is neoplasm.